TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31857300

Group type: EXPERIMENTAL
Intervention: Nasal high-flow (NHF) therapy
Number of subjects: 1512

Group type: COMPARATOR
Intervention: Standard-oxygen therapy
Number of subjects: 1512
Study: 29157898

Group type: EXPERIMENTAL
Intervention: Bioinductive collagen implant
Number of subjects: 33
Study: 25505013

Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 321

Group type: COMPARATOR
Intervention: Nonsmoking
Number of subjects: 321
Study: 24588965

Group type: EXPERIMENTAL
Intervention: miR-124
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic curves analysis
Number of subjects: 65
Study: 22918005

Group type: EXPERIMENTAL
Intervention: Resin cement (Smartcem 2)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Glass ionomer cement (GIC) (GC Luting and Lining cement)
Number of subjects: 50
Study: 20455988

Group type: EXPERIMENTAL
Intervention: Rate control strategy
Number of subjects: 2876

Group type: COMPARATOR
Intervention: Rhythm control strategy
Number of subjects: 2876
Study: 16967034

Group type: EXPERIMENTAL
Intervention: Interlocking nails
Number of subjects: 53

Group type: COMPARATOR
Intervention: Expandable nails
Number of subjects: 53
Study: 16004252

Group type: EXPERIMENTAL
Intervention: Toothpaste with differing RDA and REA values
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional toothpastes
Number of subjects: 0
Study: 12349893

Group type: EXPERIMENTAL
Intervention: Extended-duration low-molecular-weight heparin therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard postoperative prophylaxis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prophylaxis after hospital discharge
Number of subjects: 0
Study: 10200438

Group type: EXPERIMENTAL
Intervention: Visual 'go' signal with accompanying loud acoustic stimulus
Number of subjects: 14

Group type: COMPARATOR
Intervention: Visual 'go' signal without accompanying loud acoustic stimulus
Number of subjects: 14
Study: 7787356

Group type: EXPERIMENTAL
Intervention: Experimental group with rotating hemostatic valve and modified technique
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group with routine TBDC placement using Accustick system
Number of subjects: 20
Study: 30117760

Group type: EXPERIMENTAL
Intervention: Restorative yoga (Group R)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Vigorous yoga (Group V)
Number of subjects: 42
Study: 28338223

Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 26198921

Group type: EXPERIMENTAL
Intervention: GNbAC1 at 2mg/kg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: GNbAC1 at 6mg/kg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: GNbAC1
Number of subjects: 10
Study: 24030613

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 341

Group type: COMPARATOR
Intervention: Psychodynamic supportive therapy
Number of subjects: 341
Study: 19939653

Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Plant stanol ester spread (2 g/day)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo spread
Number of subjects: 150
Study: 19880936

Group type: EXPERIMENTAL
Intervention: Stepped care intervention consisting of behaviour change counselling, motivational enhancement therapy, and referral to a community alcohol treatment agency.
Number of subjects: 112

Group type: COMPARATOR
Intervention: Minimal intervention delivered by a practice nurse (control group).
Number of subjects: 112
Study: 16800138

Group type: EXPERIMENTAL
Intervention: Local anesthesia (5 cc of 1% mepivacaine solution)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control group (no anesthesia)
Number of subjects: 131
Study: 15184979

Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg once daily for 6 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10910028

Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg daily)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Simvastatin (40 mg daily)
Number of subjects: 9
Study: 9341968

Group type: EXPERIMENTAL
Intervention: apoE3/2 phenotype in psoriasis vulgaris patients
Number of subjects: 100

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: epsilon 2 allele frequency in psoriasis vulgaris patients
Number of subjects: 100
Study: 8449075

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen (1-2 L/min) for 10 min
Number of subjects: 14

Group type: COMPARATOR
Intervention: Room air
Number of subjects: 14
Study: 3022512

Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg daily
Number of subjects: 10
Study: 30059188

Group type: EXPERIMENTAL
Intervention: Curcumin (300 mg) twice daily
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Lycopene (8 mg) twice daily
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (once daily)
Number of subjects: 90
Study: 29078970

Group type: EXPERIMENTAL
Intervention: Acupuncture plus gabapentin (300 mg/d)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Gabapentin (300 mg/d) alone
Number of subjects: 46
Study: 26179187

Group type: EXPERIMENTAL
Intervention: Dulaglutide (0.75 mg)
Number of subjects: 492
Study: 23294495

Group type: EXPERIMENTAL
Intervention: Valsalva maneuver (VM)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Head-up tilt test (HUTT)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Korean version of the Orthostatic Grading Scale (KOGS)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: KOGS
Number of subjects: 172
Study: 21717138

Group type: EXPERIMENTAL
Intervention: Phenytoin (PHT) 100 mg immediate-release capsules
Number of subjects: 0
Study: 18435184

Group type: EXPERIMENTAL
Intervention: Visual assessment using a shade guide (Vitapan Classical)
Number of subjects: 92
Study: 16583183

Group type: EXPERIMENTAL
Intervention: Diode laser
Number of subjects: 232

Group type: COMPARATOR
Intervention: Alexandrite laser
Number of subjects: 232

Group type: COMPARATOR
Intervention: Intense pulsed light (IPL)
Number of subjects: 232
Study: 14630560

Group type: EXPERIMENTAL
Intervention: Intracoronary beta-radiation therapy (9, 12, 15 or 18 Gy at 1 mm tissue depth)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Intracoronary beta-radiation therapy without geographical miss (non-GM)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Geographical miss (GM)
Number of subjects: 181
Study: 10782630

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% added to timolol 0.5% and dorzolamide 2%
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (timolol 0.5% and dorzolamide 2% without latanoprost)
Number of subjects: 52
Study: 8615494

Group type: EXPERIMENTAL
Intervention: Fentanyl with epinephrine 1:300,000
Number of subjects: 38

Group type: COMPARATOR
Intervention: Fentanyl alone
Number of subjects: 38
Study: 1451721

Group type: COMPARATOR
Intervention: 75 mg clomipramine b.d. during active therapy
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo treatment during the initial week
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Clomipramine treatment
Number of subjects: 37
Study: 3938935

Group type: EXPERIMENTAL
Intervention: Chloroquine chemoprophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (children exposed frequently to malaria)
Number of subjects: 0
Study: 29534885

Group type: EXPERIMENTAL
Intervention: Excision followed by intralesional 5-fluorouracil/triamcinolone acetonide (5-FU/TAC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Excision followed by radiotherapy
Number of subjects: 60
Study: 26406193

Group type: EXPERIMENTAL
Intervention: Radial shockwave therapy (RSWT)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Manual therapy (ManT)
Number of subjects: 24
Study: 26412456

Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg every 2 weeks)
Number of subjects: 582

Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m² every 3 weeks)
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 582

Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 582
Study: 23698248

Group type: EXPERIMENTAL
Intervention: 8-week isolated core training program (n = 18)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (n = 18)
Number of subjects: 36
Study: 21402651

Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training combined with transcranial direct current stimulation (n=10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training combined with sham transcranial direct current stimulation (n=10)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Overground walking exercises (Control group, n=10)
Number of subjects: 30
Study: 18317067

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with carboplatin (AUC 5), irinotecan (100 mg/m²), and paclitaxel (175 mg/m²) followed by concurrent chemotherapy with carboplatin (AUC 2) and paclitaxel (45 mg/m² weekly) and gefitinib (250 mg daily) with 3-dimensional TCRT to 74 Gy
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiation
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy and gefitinib concurrent with 3-dimensional TCRT
Number of subjects: 23
Study: 16956824

Group type: EXPERIMENTAL
Intervention: Alternating deferoxamine and deferiprone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Deferoxamine monotherapy
Number of subjects: 60
Study: 15329007

Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 11705343

Group type: EXPERIMENTAL
Intervention: Portfolio intervention (group sessions with tasks from the Instrumental Enrichment Program, Philosophy for Children Program, and Project Intelligence)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Portfolio intervention
Number of subjects: 109
Study: 9202948

Group type: EXPERIMENTAL
Intervention: TTFD (1 g.day‐1 for 4 days)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 14
Study: 7949664

Group type: EXPERIMENTAL
Intervention: Toronto Stentless Porcine Valve (SPV)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Hancock II bioprosthesis
Number of subjects: 21
Study: 3124456

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate therapy
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 7
Study: 30428548

Group type: EXPERIMENTAL
Intervention: Two-year empowerment-based health-promotion school intervention
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 135
Study: 27608264

Group type: EXPERIMENTAL
Intervention: Drug use
Number of subjects: 3680

Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 3680
Study: 25068497

Group type: EXPERIMENTAL
Intervention: PCV7‐TT vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Synflorix (control vaccine)
Number of subjects: 0
Study: 22332211

Group type: COMPARATOR
Intervention: Sham injections plus prompt laser
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab injections plus prompt laser
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab injections plus deferred laser
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone acetonide injections plus prompt laser
Number of subjects: 423

Group type: COMPARATOR
Intervention: Sham injections plus prompt laser (for participants with 2 study eyes)
Number of subjects: 423
Study: 20387250

Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 160

Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 160
Study: 18508948

Group type: EXPERIMENTAL
Intervention: 375 mg oral dose of deferasirox tablets
Number of subjects: 17

Group type: COMPARATOR
Intervention: 130 mg intravenous infusion of deferasirox
Number of subjects: 17
Study: 16001345

Group type: EXPERIMENTAL
Intervention: Ultrasonic contrast agent SHU 508A
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Cirrhotic subjects
Number of subjects: 18

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 18
Study: 12492738

Group type: EXPERIMENTAL
Intervention: Triple therapy (group 4 treatment) for duodenal ulcer patients
Number of subjects: 2751

Group type: EXPERIMENTAL
Intervention: 10-day treatment
Number of subjects: 2751

Group type: EXPERIMENTAL
Intervention: Group 2 treatment
Number of subjects: 2751

Group type: EXPERIMENTAL
Intervention: Age over 60
Number of subjects: 2751

Group type: EXPERIMENTAL
Intervention: Clarithromycin resistance
Number of subjects: 2751
Study: 10805056

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Levosimendan + Isosorbide-5-mononitrate
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8723453

Group type: EXPERIMENTAL
Intervention: Clindamycin (600 mg dose, orally and intravenously)
Number of subjects: 30
Study: 1900148

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with mitomycin C (MMC), 20 mg/m2 administered intravenously once every 6 weeks for four consecutive cycles
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group receiving no further treatment after surgery
Number of subjects: 70
Study: 6394640

Group type: EXPERIMENTAL
Intervention: 1.5 mg of oestradiol percutaneously
Number of subjects: 43

Group type: COMPARATOR
Intervention: 2 mg of oestradiol orally
Number of subjects: 43
Study: 29986607

Group type: EXPERIMENTAL
Intervention: Befriending
Number of subjects: 0

Group type: COMPARATOR
Intervention: Art therapy
Number of subjects: 0
Study: 29394148

Group type: EXPERIMENTAL
Intervention: Intermittent hypoxic training (IHT) at FI02 = 10.6-11.4%
Number of subjects: 15

Group type: COMPARATOR
Intervention: Normoxic group (NG) exercising at ambient air
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intermittent hypoxic training (IHT)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Normoxic group (NG)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intermittent hypoxic training (IHT) and Normoxic group (NG)
Number of subjects: 15
Study: 27302510

Group type: COMPARATOR
Intervention: Conventional radiation therapy (CR)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Hypofractionated tomotherapy (TT)
Number of subjects: 108
Study: 1358483

Group type: EXPERIMENTAL
Intervention: Group 1 (discontinued treatment when serum TSH level and TBII activity normalized)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Group 2 (treated for 24 months irrespective of serum TSH level and TBII activity)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Group 1
Number of subjects: 163

Group type: COMPARATOR
Intervention: Group 2
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Clinical and laboratory parameters
Number of subjects: 163
Study: 20589566

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of Fluoxetine and CBT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18331130

Group type: EXPERIMENTAL
Intervention: Maternal education
Number of subjects: 0
Study: 15818102

Group type: EXPERIMENTAL
Intervention: Omeprazole suspension (40 mg doses on day 1, then 40 mg daily for up to 14 days)
Number of subjects: 359

Group type: COMPARATOR
Intervention: Cimetidine (300 mg bolus and 50 mg/hr for up to 14 days)
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Omeprazole suspension
Number of subjects: 359

Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 359
Study: 12201080

Group type: EXPERIMENTAL
Intervention: BDP Modulite (1000 micrograms twice-daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: BDP-CFC (Becloforte)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extrafine BDP-HFA (QVAR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CFC products
Number of subjects: 0
Study: 10495335

Group type: EXPERIMENTAL
Intervention: Constant output nebulization (5 min)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Breath-synchronized nebulization (5 min)
Number of subjects: 165
Study: 8758093

Group type: EXPERIMENTAL
Intervention: AmBisome 2mg/kg on days 1, 2, 3, 4, 5, 6, and 10 (total dose 14 mg/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: AmBisome 2 mg/kg on days 1, 2, 3, 4, and 10 (total dose 10 mg/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: AmBisome 2 mg/kg on days 1, 5 and 10 (total dose 6 mg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 30
Study: 1753719

Group type: EXPERIMENTAL
Intervention: 600 mg caffeine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 300 mg caffeine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 36
Study: 3830953

Group type: EXPERIMENTAL
Intervention: Roux-en-Y reconstruction (RY)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Longmire-Mouchet reconstruction (LM)
Number of subjects: 22
Study: 30882527

Group type: EXPERIMENTAL
Intervention: Low-intensity aerobic training by cycle ergometer
Number of subjects: 37

Group type: COMPARATOR
Intervention: Conventional physiotherapy (including occupational therapy)
Number of subjects: 37
Study: 29801156

Group type: EXPERIMENTAL
Intervention: B‐Con training
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Instructional flashcards
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Audio kits with embedded flashcards
Number of subjects: 465

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 465
Study: 27855428

Group type: EXPERIMENTAL
Intervention: Guided square dance exercise 60‐90 min at least 5 times per week for 3 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 50
Study: 25199619

Group type: EXPERIMENTAL
Intervention: lifestyle intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: standard care
Number of subjects: 40
Study: 22361318

Group type: EXPERIMENTAL
Intervention: Dexamethasone intravitreal implant 0.7 mg (Ozurdex)
Number of subjects: 690
Study: 20554790

Group type: EXPERIMENTAL
Intervention: Calcium carbonate (1500 mg Ca/d)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 21864399

Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment intervention by a specialist physician in geriatric medicine
Number of subjects: 400

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 400
Study: 16060203

Group type: EXPERIMENTAL
Intervention: Homeopathic medicine (individually prescribed) for 6 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (sugar granules) for 6 weeks
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Homeopathic medicine (individually prescribed) during open follow-up
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (sugar granules) during open follow-up
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Homeopathic medicine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 12361129

Group type: EXPERIMENTAL
Intervention: 2% erythromycin gel
Number of subjects: 208

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 208
Study: 9832293

Group type: EXPERIMENTAL
Intervention: 0.25 mg x ml(‐1) oxymetazoline (Group B)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 0.5 mg x ml(‐1) oxymetazoline (Group C)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (Group A)
Number of subjects: 36
Study: 8018452

Group type: EXPERIMENTAL
Intervention: Low dose lofepramine (70 mg once daily)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 2919736

Group type: EXPERIMENTAL
Intervention: Reperitonealization of the gallbladder bed
Number of subjects: 88

Group type: COMPARATOR
Intervention: Raw surface left uncovered (Control)
Number of subjects: 88
Study: 29235884

Group type: EXPERIMENTAL
Intervention: Vortioxetine (10-20 mg/day)
Number of subjects: 344

Group type: COMPARATOR
Intervention: Duloxetine (60 mg/day)
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Vortioxetine (10-20 mg/day) with UPSA score change ≥9
Number of subjects: 344

Group type: COMPARATOR
Intervention: Duloxetine (60 mg/day) with UPSA score change ≥9
Number of subjects: 344
Study: 29081922

Group type: EXPERIMENTAL
Intervention: Bifeprunox
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26436422

Group type: EXPERIMENTAL
Intervention: Tetranychus cinnabarinus (Boisd.) protonymphs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bemisia tabaci (Gennadius) eggs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mix of T. cinnabarinus protonymphs and B. Tabaci eggs
Number of subjects: 0

Group type: COMPARATOR
Intervention: B. Tabaci eggs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mix of both prey
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: T. cinnabarinus
Number of subjects: 0
Study: 24219579

Group type: EXPERIMENTAL
Intervention: Dietary intervention for lowering uric acid (education package)
Number of subjects: 19724

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 19724
Study: 20936577

Group type: EXPERIMENTAL
Intervention: Pelvic examination training by a gynecological teaching associate (GTA) alone
Number of subjects: 106

Group type: COMPARATOR
Intervention: Pelvic examination training by a standardized patient (SP) with an obstetrics and gynecology faculty member
Number of subjects: 106
Study: 18634549

Group type: EXPERIMENTAL
Intervention: Postoperative physiotherapy
Number of subjects: 184

Group type: COMPARATOR
Intervention: Standard care nursing and medical interventions (Control Group)
Number of subjects: 184
Study: 16782312

Group type: EXPERIMENTAL
Intervention: Antidepressants (95% were selective serotonin or norepinephrine reuptake inhibitors, or second-generation antidepressants)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Antidepressants (with concurrent mood stabilizer)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Usual care without antidepressants
Number of subjects: 182
Study: 14504184

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg daily for 8 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Aspirin 100 mg daily for 8 weeks
Number of subjects: 50